Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 80 articles:
HTML format



Single Articles


    August 2021
  1. FOSSUM CC, Xiong Y, Magliocco A, Daneshmand S, et al
    Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2021;41:3851-3857.
    PubMed     Abstract available


  2. MUKAE Y, Ito H, Miyata Y, Araki K, et al
    Ceruloplasmin Levels in Cancer Tissues and Urine Are Significant Biomarkers of Pathological Features and Outcome in Bladder Cancer.
    Anticancer Res. 2021;41:3815-3823.
    PubMed     Abstract available


  3. MASILAMANI AP, Fischer A, Schultze-Seemann S, Kuckuck I, et al
    Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer.
    Anticancer Res. 2021;41:3741-3746.
    PubMed     Abstract available


  4. MATSUNAGA W, Hamada K, Tagawa M, Morinaga T, et al
    Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector.
    Anticancer Res. 2021;41:3731-3740.
    PubMed     Abstract available


    June 2021
  5. OKUBO K, Isono M, Asano T, REssING N, et al
    Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
    Anticancer Res. 2021;41:2901-2912.
    PubMed     Abstract available


    May 2021
  6. XIAO H, Alisic H, Reiman BT, Deng Z, et al
    IL-39 Reduces Proliferation and Promotes Apoptosis of Bladder Cancer by Altering the Activity of Cyclin E and Fas.
    Anticancer Res. 2021;41:2239-2245.
    PubMed     Abstract available


    December 2020
  7. ADELMANN TG, Camerota TC, Ceausu AR, Cimpean AM, et al
    Chloride Intracellular Channel Protein 1 (CLIC1) Iotas Over-expressed in Muscle Invasive Urinary Bladder Cancer.
    Anticancer Res. 2020;40:6879-6884.
    PubMed     Abstract available


    November 2020
  8. PAN Y, Chiu YH, Chiu SC, Cho DY, et al
    Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Anticancer Res. 2020;40:6093-6099.
    PubMed     Abstract available


  9. SUN YU, Nishino H, Sugisawa N, Yamamoto J, et al
    Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
    Anticancer Res. 2020;40:6083-6091.
    PubMed     Abstract available


    October 2020
  10. MAJEWSKI W, Nieckula J, Dworzecki T, Miszczyk L, et al
    Bladder-conserving Approach in Radical Treatment of Patients With Bladder Cancer - A Single-institution Experience.
    Anticancer Res. 2020;40:5861-5868.
    PubMed     Abstract available


    September 2020
  11. YAMAMOTO S, Kageyama Y, Fujii Y, Aizawa T, et al
    Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer.
    Anticancer Res. 2020;40:5295-5299.
    PubMed     Abstract available


  12. PAN Y, Chiu YH, Chiu SC, Cho DY, et al
    Gamma/Delta T-Cells Enhance Carboplatin-induced Cytotoxicity Towards Advanced Bladder Cancer Cells.
    Anticancer Res. 2020;40:5221-5227.
    PubMed     Abstract available


    August 2020
  13. HAGA N, Tsubouchi K, Maruta H, Koguchi T, et al
    Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor.
    Anticancer Res. 2020;40:4299-4307.
    PubMed     Abstract available


  14. TAKEMOTO K, Teishima J, Kohada Y, Ikeda K, et al
    The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
    Anticancer Res. 2020;40:4787-4793.
    PubMed     Abstract available


    July 2020
  15. BARAK V, Itzkovich D, Einarsson R, Gofrit O, et al
    Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology.
    Anticancer Res. 2020;40:3967-3972.
    PubMed     Abstract available


    May 2020
  16. ADACHI A, Kawamura H, Yoshida D, Kawahara M, et al
    Whole-bladder Radiation Therapy for Lymph Node-negative Bladder Cancer With Muscle Invasion in Elderly Patients.
    Anticancer Res. 2020;40:2905-2909.
    PubMed     Abstract available


  17. HUANG CP, Liu LX, Shyr CR
    Tumor-associated Macrophages Facilitate Bladder Cancer Progression by Increasing Cell Growth, Migration, Invasion and Cytokine Expression.
    Anticancer Res. 2020;40:2715-2724.
    PubMed     Abstract available


    April 2020
  18. CHEN M, Chang WS, Shen TC, Gong CL, et al
    Association of Nijmegen Breakage Syndrome 1 Genotypes With Bladder Cancer Risk.
    Anticancer Res. 2020;40:2011-2017.
    PubMed     Abstract available


    March 2020
  19. YU J, Lu Y, Muto S, Ide H, et al
    The Dual Function of Aryl Hydrocarbon Receptor in Bladder Carcinogenesis.
    Anticancer Res. 2020;40:1345-1357.
    PubMed     Abstract available


    December 2019
  20. LIU J, Li S, Cheng X, DU P, et al
    HOXB2 is a Putative Tumour Promotor in Human Bladder Cancer.
    Anticancer Res. 2019;39:6915-6921.
    PubMed     Abstract available


  21. LEE MY, Shi CS, Hsu YC, Huang KJ, et al
    Honokiol Is a Potential Therapeutic Agent and Has a Synergistic Effect With 5-FU in Human Urothelial Cell Carcinoma Cells.
    Anticancer Res. 2019;39:6555-6565.
    PubMed     Abstract available


    September 2019
  22. CHEN M, Tsai YT, Chang WS, Shih LC, et al
    Association of Caspase-8 Genotypes With Bladder Cancer Risk.
    Anticancer Res. 2019;39:4767-4773.
    PubMed     Abstract available


    August 2019
  23. AKITAKE M, Yamaguchi A, Shiota M, Imada K, et al
    Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2019;39:4325-4328.
    PubMed     Abstract available


    July 2019
  24. CHIANG CH, Yeh CY, Chung JG, Chiang IT, et al
    Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer.
    Anticancer Res. 2019;39:3641-3649.
    PubMed     Abstract available


    May 2019
  25. NAKAMURA Y, Miyata Y, Takehara K, Asai A, et al
    The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.
    Anticancer Res. 2019;39:2317-2324.
    PubMed     Abstract available


    April 2019
  26. HANADA E, Kageyama S, Murai R, Kubota S, et al
    Pro-GA, a Novel Inhibitor of gamma-Glutamylcyclotransferase, Suppresses Human Bladder Cancer Cell Growth.
    Anticancer Res. 2019;39:1893-1898.
    PubMed     Abstract available


  27. HUANG AC, Cheng YD, Huang LH, Hsiao YT, et al
    Casticin Induces DNA Damage and Impairs DNA Repair in Human Bladder Cancer TSGH-8301 Cells.
    Anticancer Res. 2019;39:1839-1847.
    PubMed     Abstract available


    March 2019
  28. VASYUTIN I, Zerihun L, Ivan C, Atala A, et al
    Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling.
    Anticancer Res. 2019;39:1105-1118.
    PubMed     Abstract available


    February 2019
  29. KUSUHARA Y, Daizumoto K, Kawai K, Hirayama K, et al
    Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer.
    Anticancer Res. 2019;39:703-711.
    PubMed     Abstract available


  30. KUMAGAI-TOGASHI A, Uozaki H, Kikuchi Y, Watabe S, et al
    Tumorous CD10 Is More Strongly Related to the Progression of Urothelial Carcinoma than Stromal CD10.
    Anticancer Res. 2019;39:635-640.
    PubMed     Abstract available


    December 2018
  31. RADES D, Sondermann L, Motisi L, Janssen S, et al
    Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder.
    Anticancer Res. 2018;38:6841-6846.
    PubMed     Abstract available


    September 2018
  32. TSAI TH, Wang YM, Chang WS, Tsai CW, et al
    Association of Matrix Metalloproteinase-8 Genotypes with the Risk of Bladder Cancer.
    Anticancer Res. 2018;38:5159-5164.
    PubMed     Abstract available


  33. LEA MA, Kim H, desBORDES C
    Effects of Biguanides on Growth and Glycolysis of Bladder and Colon Cancer Cells.
    Anticancer Res. 2018;38:5003-5011.
    PubMed     Abstract available


    August 2018
  34. NAKAMURA R, Kakuhara H, Kikuchi K, Segawa T, et al
    Partial Bladder Boost Using Lipiodol Marking During Image-guided Radiotherapy for Bladder Cancer.
    Anticancer Res. 2018;38:4827-4831.
    PubMed     Abstract available


  35. TSAI KW, Kuo WT, Jeng SY
    Tight Junction Protein 1 Dysfunction Contributes to Cell Motility in Bladder Cancer.
    Anticancer Res. 2018;38:4607-4615.
    PubMed     Abstract available


  36. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.
    Anticancer Res. 2018;38:4759-4766.
    PubMed     Abstract available


    July 2018
  37. GOUSSIA AC, Papoudou-Bai A, Charchanti A, Kitsoulis P, et al
    Alterations of p53 and Rb Pathways Are Associated with High Proliferation in Bladder Urothelial Carcinomas.
    Anticancer Res. 2018;38:3985-3988.
    PubMed     Abstract available


    June 2018
  38. MOURMOURAS N, Philippou A, Christopoulos P, Kostoglou K, et al
    Differential Expression of IGF-I Transcripts in Bladder Cancer.
    Anticancer Res. 2018;38:3453-3459.
    PubMed     Abstract available


  39. POSFAI B, Kuthi L, Varga L, Laczo I, et al
    The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
    Anticancer Res. 2018;38:3243-3254.
    PubMed     Abstract available


    May 2018
  40. REXIN P, Tauchert A, Hanze J, Heers H, et al
    The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.
    Anticancer Res. 2018;38:2749-2754.
    PubMed     Abstract available


  41. OWARI T, Miyake M, Nakai Y, Morizawa Y, et al
    A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
    Anticancer Res. 2018;38:3097-3103.
    PubMed     Abstract available


    April 2018
  42. KIM S, Lee AJ, Yeo MK, Na YG, et al
    Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2018;38:2429-2437.
    PubMed     Abstract available


  43. MATSUNAGA W, Ichikawa M, Nakamura A, Ishikawa T, et al
    Lentiviral Vector-mediated Gene Transfer in Human Bladder Cancer Cell Lines.
    Anticancer Res. 2018;38:2015-2020.
    PubMed     Abstract available


  44. MAKINO T, Izumi K, Natsagdorj A, Iwamoto H, et al
    Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract.
    Anticancer Res. 2018;38:2241-2245.
    PubMed     Abstract available


    March 2018
  45. MIYATA Y, Matsuo T, Nakamura Y, Yasuda T, et al
    Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
    Anticancer Res. 2018;38:1629-1635.
    PubMed     Abstract available


  46. MICHALSKA M, Schultze-Seemann S, Kuckuck I, Katzenwadel A, et al
    Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells.
    Anticancer Res. 2018;38:1369-1375.
    PubMed     Abstract available


    February 2018
  47. HEERS H, Gut JM, Hegele A, Hofmann R, et al
    Non-invasive Detection of Bladder Tumors Through Volatile Organic Compounds: A Pilot Study with an Electronic Nose.
    Anticancer Res. 2018;38:833-837.
    PubMed     Abstract available


    January 2018
  48. SOUKUP V, Capoun O, Pesl M, Sobotka R, et al
    Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
    Anticancer Res. 2018;38:239-246.
    PubMed     Abstract available


    December 2017
  49. CHEN CC, Huang CP, Tsai YT, Hseih TF, et al
    The Genomic Alterations of 5alpha-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer.
    Anticancer Res. 2017;37:6893-6898.
    PubMed     Abstract available


  50. MINAMI S, Matsumoto K, Nagashio R, Hagiuda D, et al
    Analysis of Autoantibodies Related to Tumor Progression in Sera from Patients with High-grade Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2017;37:6705-6714.
    PubMed     Abstract available


  51. SYRING I, Weiten R, Muller T, Schmidt D, et al
    The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.
    Anticancer Res. 2017;37:6685-6695.
    PubMed     Abstract available


    November 2017
  52. SCHINZARI G, Monterisi S, Pierconti F, Nazzicone G, et al
    Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Anticancer Res. 2017;37:6453-6458.
    PubMed     Abstract available


  53. LIAW CC, Chuang CK, Chang YH, Liao TY, et al
    Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
    Anticancer Res. 2017;37:6443-6451.
    PubMed     Abstract available


    October 2017
  54. AIZAWA R, Sakamoto M, Orito N, Kono M, et al
    The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients.
    Anticancer Res. 2017;37:5761-5766.
    PubMed     Abstract available


  55. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics.
    Anticancer Res. 2017;37:5603-5608.
    PubMed     Abstract available


  56. D'ANDREA D, Moschini M, Soria F, Gust KM, et al
    ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2017;37:5747-5753.
    PubMed     Abstract available


    September 2017
  57. CIMPEAN AM, Tarlui V, Cumpanas AA, Bolintineanu S, et al
    Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?
    Anticancer Res. 2017;37:4935-4942.
    PubMed     Abstract available


  58. HSU FT, Sun CC, Wu CH, Lee YJ, et al
    Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells.
    Anticancer Res. 2017;37:4919-4926.
    PubMed     Abstract available


    August 2017
  59. TANG X, Wang S, An C, DU P, et al
    Preoperative High Neutrophil-to-Lymphocyte Ratio Is Associated with High-grade Bladder Cancer.
    Anticancer Res. 2017;37:4659-4663.
    PubMed     Abstract available


  60. ZHOU HH, Liu LY, Yu GH, Qu GM, et al
    Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
    Anticancer Res. 2017;37:4529-4537.
    PubMed     Abstract available


  61. DU P, Wang S, Tang X, An C, et al
    Reduced Expression of Metastasis Suppressor-1 (MTSS1) Accelerates Progression of Human Bladder Uroepithelium Cell Carcinoma.
    Anticancer Res. 2017;37:4499-4505.
    PubMed     Abstract available


    July 2017
  62. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Urinary Bladder Cancer Patients.
    Anticancer Res. 2017;37:3537-3541.
    PubMed     Abstract available


    June 2017
  63. JANSSEN S, Manig L, Schild SE, Rades D, et al
    Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly.
    Anticancer Res. 2017;37:3287-3290.
    PubMed     Abstract available


    May 2017
  64. MANIG L, Kasmann L, Janssen S, Schild SE, et al
    Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer.
    Anticancer Res. 2017;37:2693-2696.
    PubMed     Abstract available


    April 2017
  65. SILVA J, Arantes-Rodrigues R, Pinto-Leite R, Faustino-Rocha AI, et al
    Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines.
    Anticancer Res. 2017;37:1737-1745.
    PubMed     Abstract available


  66. KHANAL A, Budhathoki N, Singh VP, Shah BK, et al
    Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
    Anticancer Res. 2017;37:2033-2036.
    PubMed     Abstract available


    March 2017
  67. RADES D, Manig L, Janssen S, Schild SE, et al
    Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
    Anticancer Res. 2017;37:1485-1488.
    PubMed     Abstract available


  68. RADES D, Manig L, Janssen S, Schild SE, et al
    A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer.
    Anticancer Res. 2017;37:1481-1484.
    PubMed     Abstract available


  69. HUDOLIN T, Mengus C, Coulot J, Kastelan Z, et al
    Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas.
    Anticancer Res. 2017;37:1375-1380.
    PubMed     Abstract available


  70. SHI CS, Li JM, Chin CC, Kuo YH, et al
    Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells.
    Anticancer Res. 2017;37:1149-1159.
    PubMed     Abstract available


    February 2017
  71. WIECZOREK E, Jablonowski Z, Tomasik B, Gromadzinska J, et al
    Different Gene Expression and Activity Pattern of Antioxidant Enzymes in Bladder Cancer.
    Anticancer Res. 2017;37:841-848.
    PubMed     Abstract available


  72. FRIEDMAN P, Lai JP
    Liver Metastasis of Urothelial Carcinoma with Hepatoid Features: An Unusual Morphological Finding.
    Anticancer Res. 2017;37:801-804.
    PubMed     Abstract available


    December 2016
  73. MANIG L, Kasmann L, Janssen S, Rades D, et al
    Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder.
    Anticancer Res. 2016;36:6663-6665.
    PubMed     Abstract available


  74. HANCOCK BM, McGuire KL, Tsuji S, Reil K, et al
    A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival.
    Anticancer Res. 2016;36:6243-6248.
    PubMed     Abstract available


    October 2016
  75. SAKAGUCHI M, Maebayashi T, Aizawa T, Ishibashi N, et al
    Clinical Results for Bladder Cancer Treated by Radiotherapy Without Concurrent Standard Chemotherapy.
    Anticancer Res. 2016;36:5519-5525.
    PubMed     Abstract available


  76. KRIEGMAIR MC, Balk M, Wirtz R, Steidler A, et al
    Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2016;36:5205-5213.
    PubMed     Abstract available


  77. IWAMOTO H, Izumi K, Shimura Y, Natsagdorj A, et al
    Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma.
    Anticancer Res. 2016;36:5557-5561.
    PubMed     Abstract available


    September 2016
  78. MAEBAYASHI T, Ishibashi N, Aizawa T, Sakaguchi M, et al
    Radiotherapy for Muscle-invasive Bladder Cancer in Very Elderly Patients.
    Anticancer Res. 2016;36:4763-9.
    PubMed     Abstract available


  79. CHANG WS, Liao CH, Tsai CW, Hu PS, et al
    Association of Enhancer of Zeste 2 (EZH2) Genotypes with Bladder Cancer Risk in Taiwan.
    Anticancer Res. 2016;36:4509-14.
    PubMed     Abstract available


    August 2016
  80. HAHN AW, Giri S, Pathak R, Bhatt VR, et al
    Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract.
    Anticancer Res. 2016;36:4051-5.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: